SCHEMBL21484809

SCHEMBL21484809

N#C/C(=C\c1ccc(O)c(O)c1)C(=O)Nc1nc(-c2ccc(C(=O)O)cc2)cs1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 11/20 0.53
ERBB2 P04626 6/20 0.53
KDM4E B2RXH2 5/20 0.53
MEN1 O00255 5/20 0.53
TP53 P04637 5/20 0.53
CYP3A4 P08684 5/20 0.53
MAPT P10636 5/20 0.53
ALOX15 P16050 5/20 0.53
ALOX12 P18054 5/20 0.53
MAPK1 P28482 5/20 0.53
BLM P54132 5/20 0.53
PMP22 Q01453 5/20 0.53
KMT2A Q03164 5/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
HSD17B10 Q99714 5/20 0.53
TDP1 Q9NUW8 5/20 0.53
RGS12 O14924 4/20 0.53
CYP1A2 P05177 4/20 0.53
GNAI1 P63096 4/20 0.53
ALDH1A1 P00352 4/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484810 1.00 EGFR (0.53) EGFRERBB2KDM4EMEN1TP53
SCHEMBL21484888 0.91 EGFR (0.60) EGFRERBB2KDM4EMEN1TP53
SCHEMBL21484629 0.91 EGFR (0.62) EGFRERBB2KDM4EMEN1TP53
SCHEMBL28515561 0.90 EGFR (0.51) EGFRERBB2KDM4EMEN1TP53
SCHEMBL30186427 0.90 EGFR (0.51) EGFRERBB2KDM4EMEN1TP53
SCHEMBL21505875 0.90 EGFR (0.51) EGFRERBB2KDM4EMEN1TP53
SCHEMBL21484650 0.89 PTGS2 (0.64) EGFRERBB2KDM4EMEN1TP53
SCHEMBL21484837 0.89 LMNA (0.54) EGFRERBB2KDM4EMEN1TP53
SCHEMBL21484607 0.89 MRE11 (0.56) EGFRERBB2KDM4EMEN1TP53
SCHEMBL21484665 0.89 MRE11 (0.56) EGFRERBB2KDM4EMEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
EP-3556755-B1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES UNIV MASARYKOVA (CZ) 2021-11-17 EP disclosed
EP-3556755-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES Masarykova univerzita (CZ) 2019-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 EGFR 1661/4885ERBB2 2095/4885KDM4E 1848/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 EGFR 1661/4885ERBB2 2095/4885KDM4E 1848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.